 As highlighted by the National Clinical Advisory Board of the National Multiple Sclerosis Society NMSS, fatigue is the most common MS multiple sclerosis symptom, affecting up to 95 of individuals. Higher levels of cognitive fatigue have been associated with poorer quality of life Amato Portaccio, 2012 and increased disability Lapierre Hum, 2007, negatively affecting wellness. Several medications are currently prescribed to individuals with MS who suffer from fatigue, such as amantadine and modafinil. However, the effect of these medications on decreasing fatigue levels in individuals with MS is suboptimal e.g. Stankoff et al., 2005. At the same time, there is overwhelming evidence showing that methylphenidate is effective at relieving fatigue in individuals with cancer Minton et al., 2013, human immunodeficiency virus Breitbart, Rosenfeld, Kaim, Funesti-Esch, 2001, Parkinsons disease Devos et al., 2013 and chronic fatigue syndrome CFS Blockmans et al., 2006. For example, individuals with CFS reported decreased fatigue levels as measured with a visual analogue scale when taking MP Blockmans et al., 2006. Although MP has been demonstrated to be an effective fatigue-relieving drug in multiple clinical populations discussed above, the effect of MP on MS-related fatigue has not been objectively tested. 